This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 29/1/114    most recent ATVBAHA.108.172247v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dentelli, P. Articles by Brizzi, M. F. Search for Related Content PubMed PubMed Citation Articles by Dentelli, P. Articles by Brizzi, M. F. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:114.)
© 2009 American Heart Association, Inc.

Cell Biology/Signaling

Formation of STAT5/PPAR Transcriptional Complex Modulates Angiogenic Cell Bioavailability in Diabetes

Patrizia Dentelli; Antonella Trombetta; Gabriele Togliatto; Annarita Zeoli; Arturo Rosso; Barbara Uberti; Francesca Orso; Daniela Taverna; Luigi Pegoraro; Maria Felice Brizzi

From the Department of Internal Medicine (P.D., A.T., G.T., A.Z., A.R., B.U., L.P., M.F.B.) and the Molecular Biotechnology Center and Department Oncological Sciences (F.O., D.T.), University of Torino, Italy.

Correspondence to Maria Felice Brizzi, MD, Department of Internal Medicine, University of Torino, Corso Dogliotti 14, 10126, Torino, Italy. E-mail mariafelice.brizzi{at}unito.it

Objective— Circulating angiogenic cells (CACs) expansion is a multistage process requiring sequential activation of transcriptional factors, including STAT5. STAT5, in concert with peroxisome proliferator-activated receptors (PPARs), seems to induce discrete biological responses in different tissues. In the present study we investigated the role of STAT5 and PPAR in regulating CAC expansion in normal and diabetic settings.

Methods and Results— Normal and diabetic CACs were used. siRNA technology, EMSA, and chromatin immunoprecipitation (ChIP) assay as well as site-directed mutagenesis of the STAT5 response element in the PPAR promoter enabled us to demonstrate that STAT5 transcriptional activity controls PPAR expression. Moreover, FACS analysis, coimmunoprecipitation experiments, and ChIP assay revealed that a STAT5/PPAR transcriptional complex controls cyclin D1 expression and CAC progression into the cell-cycle. Conversely, PPAR agonists, by preventing the expression of STAT5 and the formation of the STAT5/PPAR heterodimeric complex failed to promote CAC expansion. Finally, we demonstrated that diabetic CAC functional capability can be recovered by molecules able to activate the STAT5/PPAR transcriptional complex.

Conclusions— Our data identify the STAT5/PPAR heterodimers as landmark of CAC expansion and provide evidences for a mechanism that partially rescues CAC bioavailability in diabetic setting.

We investigated the role of STAT5 and PPAR in regulating CAC expansion in normal and diabetic settings. We provide evidences that STAT5 controls PPAR expression and the formation of a STAT5/PPAR transcriptional complex, which is a permissive event for normal and diabetic CAC expansion.

Key Words: STAT5 • PPAR • diabetes • EPC • angiogenesis

Related Article:

Vascular Remodeling in Diabetes: Don’t Leave Without Your STAT5

Anna Zampetaki and Qingbo Xu
Arterioscler Thromb Vasc Biol 2009 29: 10-11. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. Zampetaki and Q. Xu Vascular Remodeling in Diabetes: Don't Leave Without Your STAT5 Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 10 - 11. [Full Text] [PDF]